Statement: There was twice as many Cardiac adverse events as cases of Dyspnea in cohort 1 of the primary trial.
Primary_evidence: Adverse Events 1:   Total: 6/22 (27.27%)   Cardiac General, other1/22 (4.55%)   Pain - Abdomen NOS1/22 (4.55%)   Death not assoc w CTCAE term- Death NOS1/22 (4.55%)   Death not assoc w CTCAE term-Disease prog NOS1/22 (4.55%)   Liver dysfunction/failure1/22 (4.55%)   Sodium, low (hyponatremia)1/22 (4.55%)   Dyspnea (shortness of breath)2/22 (9.09%)